Using Renal Disease to Predict Cardiovascular Risk

renal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysisrenal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysis

renal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysisrenal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysis

renal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysisrenal disease, cardiovascular disease, estimated globmerular filtration rate, eGFR, urinary albumin-creatinine ratio, UACR, ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease, vascular disease, diabetes, cardiovascular death, myocardial infarction, stroke, hospitalization, dialysis